Transforming science into medicine

We are committed to developing novel compounds in oncology that will deliver life-changing innovations for patients.

Press Release January 4, 2023

BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer

Upcoming Event February 15, 2023

BioLineRx Management and Medical Affairs Team at Tandem

Pipeline

Motixafortide (BL-8040)

Stem Cell Mobilization

Motixafortide (BL-8040) blocks the interaction between CXCL12 and CXCR4 leading to robust mobilization of stem cells to the peripheral blood for collection and transplant.

Pipeline

Motixafortide (BL-8040)

Solid Tumors

Motixafortide (BL-8040) mobilizes immune cells to peripheral blood circulation, leading to Increase in immune cell infiltration into tumors and reduction in immunosuppression in tumor microenvironment.

Pipeline

AGI-134

Solid Tumors

AGI-134 is a universal drug that evokes a vaccine effect via a unique, hyper-acute, multi-arm mechanism that targets patient-specific neoantigens

Partnering

In-licensing
BioLineRx is committed to the identification, in-licensing and systematic development of promising therapeutic candidates. Through this strategy, BioLineRx is building a pipeline of powerful technologies in oncology.

Out-licensing
BioLineRx seeks to collaborate with leading global pharmaceutical companies with a proven track record in clinical experience, for completion of the final phases of the clinical trials, and commercial capabilities, to successfully bring our innovative developments to market. We believe that this is the way to combine our drug development expertise with your commercial development capabilities.

Investors

Delayed up to 30 minutes - See terms
Delayed up to 30 minutes - See terms